6564.TWO
Price:
$20
Market Cap:
$1.44B
Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.
Industry
Biotechnology
IPO Date
2018-09-18
Stock Exchange
TWO
Ticker
6564.TWO
According to Enimmune corporation’s latest financial reports and current stock price. The company's current ROE is -70.32%. This represents a change of 121.37% compared to the average of -31.77% of the last 4 quarters.
The mean historical ROE of Enimmune corporation over the last ten years is -32.50%. The current -70.32% ROE has changed 116.36% with respect to the historical average. Over the past ten years (40 quarters), 6564.TWO's ROE was at its highest in in the June 2019 quarter at 0%. The ROE was at its lowest in in the December 2023 quarter at -45.36%.
Average
-32.50%
Median
-29.81%
Minimum
-69.50%
Maximum
-8.29%
Discovering the peaks and valleys of Enimmune corporation ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 449.40%
Maximum Annual ROE = -8.29%
Minimum Annual Increase = -39.40%
Minimum Annual ROE = -69.50%
| Year | ROE | Change |
|---|---|---|
| 2024 | -42.12% | -39.40% |
| 2023 | -69.50% | 52.62% |
| 2022 | -45.54% | 449.40% |
| 2021 | -8.29% | -31.28% |
| 2020 | -12.06% | -31.08% |
The current ROE of Enimmune corporation (6564.TWO) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-52.38%
5-year avg
-35.50%
10-year avg
-32.50%
Enimmune corporation’s ROE is greater than NaviFUS Corp. (-20.73%), greater than GeneReach Biotechnology Corp. (-19.92%), greater than Great Novel Therapeutics Biotech & Medicals (-14.66%), greater than MegaPro Biomedical Co., Ltd (-91.17%), less than Abnova (Taiwan) Corporation (-0.51%), greater than Bio Preventive Medicine Corp. (-24.73%), greater than LabTurbo Biotech Corporation (-12.54%), less than BiOptic Inc. (4.93%), greater than Lukas Biomedical Inc. (-31.59%), less than GenMont Biotech Incorporation (1.18%),
| Company | ROE | Market cap |
|---|---|---|
| -20.73% | $1.45B | |
| -19.92% | $1.10B | |
| -14.66% | $1.48B | |
| -91.17% | $1.02B | |
| -0.51% | $1.38B | |
| -24.73% | $1.14B | |
| -12.54% | $1.12B | |
| 4.93% | $1.36B | |
| -31.59% | $1.33B | |
| 1.18% | $1.59B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Enimmune corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Enimmune corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Enimmune corporation's ROE?
How is the ROE calculated for Enimmune corporation (6564.TWO)?
What is the highest ROE for Enimmune corporation (6564.TWO)?
What is the 3-year average ROE for Enimmune corporation (6564.TWO)?
What is the 5-year average ROE for Enimmune corporation (6564.TWO)?
How does the current ROE for Enimmune corporation (6564.TWO) compare to its historical average?